Manjaro
2 statements across 1 episodes · 2 bullish · 0 bearish · 1 people on the record · first statement Nov 13, 2024 by Dr. Mike Israetel · across every show →
Everything said about Manjaro, oldest first
Nov 13, 2024 bullish
Israetel: Tirzepatide outperforms Ozempic, with more potent fifth-gen GLP drugs in trials
“Technically it's a third generation GLP drug, but fourth gen is Trisapatide. It's already on the market, Manjaro. Fewer side effects, bigger primary effect. There are fifth gen drugs currently in FDA approval process, which make Ozempic look like a starter pac…”
Nov 13, 2024 positive
Israetel: GLP-1 drugs curb obesity primarily by lowering genetic food drive
“New medications like Ozempic, Trisapatide, et cetera, Manjaro, all those things. While, why they were some of the only things to really take a big chunk out of obesity is because they take your, whatever genetic food drive and palatability drive you have, how …”